Key result
EMD-57033 boosts porcine myocardial contractility by reducing super-relaxed myosin heads and altering the troponin complex.
Why the study?
There are no available therapeutics that directly target contractile proteins to improve myocardium contractility and reduce mortality in heart failure.
Does EMD-57033 augment contractility in permeabilized porcine myocardium?
Does EMD-57033 augment contractility in permeabilized porcine myocardium?
EMD-57033 demonstrates a dual mechanism of activating myosin heads and the troponin complex to augment myocardial contractility, supporting the development of small molecule myotropes for heart failure.
May guide myotrope development for HF; leaves open translation to human myocardium.
Sufficient cardiac contractility is necessary to ensure the sufficient cardiac output to provide an adequate end-organ perfusion. Inadequate cardiac output and the diminished perfusion of vital organs from depressed myocardium contractility is a hallmark end-stage of heart failure. There are no available therapeutics that directly target contractile proteins to improve the myocardium contractility and reduce mortality. The purpose of this study is to present a proof of concept to aid in the development of muscle activators (myotropes) for augmenting the contractility in clinical heart failure. Here we use a combination of cardiomyocyte mechanics, the biochemical quantification of the ATP turnover, and small angle X-ray diffraction on a permeabilized porcine myocardium to study the mechanisms of EMD-57033 (EMD) for activating myosin. We show that EMD increases the contractility in a porcine myocardium at submaximal and systolic calcium concentrations. Biochemical assays show that EMD decreases the proportion of myosin heads in the energy sparing super-relaxed (SRX) state under relaxing conditions, which are less likely to interact with actin during contraction. Structural assays show that EMD moves the myosin heads in relaxed muscles from a structurally ordered state close to the thick filament backbone, to a disordered state closer to the actin filament, while simultaneously inducing structural changes in the troponin complex on the actin filament. The dual effects of EMD on activating myosin heads and the troponin complex provides a proof of concept for the use of small molecule muscle activators for augmenting the contractility in heart failure.
No takes yet. Share an insight, caveat, or question.
Jani et al. (2022) studied Heart failure. EMD-57033 was evaluated on Myocardium contractility and myosin activation. EMD-57033 increased contractility in porcine myocardium by decreasing myosin heads in the super-relaxed state and inducing structural changes in the troponin complex.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: